PROPHYLACTIC 1α‐HYDROXYVITAMIN D3 THERAPY IN HAEMODIALYSIS PATIENTS

G. S. WALKER, M. PEACOCK, J. AARON, P. J.A. ROBINSON, A. M. DAVISON

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Twenty‐seven patients starting regular haemodialysis were treated with a 1 μg daily dose of l α‐hydroxyvitamin D3 and concurrent aluminium hydroxide therapy to prevent hyperphosphataemia. There was an increase in plasma calcium, but no significant improvement in plasma alkaline phosphatase activity or parathyroid hormone levels. Metastatic calcification progressed but was never a severe clinical problem. Quantitative bone histology showed a significant decrease in resorptive surfaces confirmed radiologically, but there was no significant decrease in forming surfaces. The expected increase in forming surfaces with length of dialysis was however prevented.

Original languageEnglish (US)
Pages (from-to)125s-130s
JournalClinical Endocrinology
Volume7
DOIs
StatePublished - Dec 1977

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'PROPHYLACTIC 1α‐HYDROXYVITAMIN D<sub>3</sub> THERAPY IN HAEMODIALYSIS PATIENTS'. Together they form a unique fingerprint.

  • Cite this

    WALKER, G. S., PEACOCK, M., AARON, J., ROBINSON, P. J. A., & DAVISON, A. M. (1977). PROPHYLACTIC 1α‐HYDROXYVITAMIN D3 THERAPY IN HAEMODIALYSIS PATIENTS. Clinical Endocrinology, 7, 125s-130s. https://doi.org/10.1111/j.1365-2265.1977.tb03372.x